TABLE 1.
Patient demographics and clinicopathologic characteristics in two cohorts
| Primary cohort (N = 1,012) |
Validation cohort (N = 1,213) |
P | |
|---|---|---|---|
| Age | 61.9 ± 12.8 | 60.1 ± 12.6 | <0.01 |
| Sex | 0.34 | ||
| Male | 601 (59.4%) | 695 (57.3%) | |
| Female | 411 (40.6%) | 518 (42.7%) | |
| T Status | <0.01 | ||
| 1 | 32 (3.2%) | 9 (0.7%) | |
| 2 | 168 (16.6%) | 78 (6.4%) | |
| 3 | 723 (71.4%) | 705 (58.1%) | |
| 4 | 89 (8.8%) | 421 (34.7%) | |
| N Status | <0.01 | ||
| 0 | 586 (57.9%) | 815 (67.2%) | |
| 1 | 283 (28.0%) | 245 (20.2%) | |
| 2 | 143 (14.1%) | 153 (12.6%) | |
| TNM Stage | <0.01 | ||
| I | 168 (16.6%) | 75 (6.2%) | |
| II | 415 (41.0%) | 735 (60.6%) | |
| III | 409 (40.4%) | 378 (31.2%) | |
| IV | 20 (2.0%) | 25 (2.1%) | |
| Location | 0.04 | ||
| Colon | 523 (51.7%) | 573 (47.2%) | |
| Rectum | 489 (48.3%) | 640 (52.8%) | |
| CEA | 0.09 | ||
| Normal | 650 (64.2%) | 752 (62.0%) | |
| Abnormal | 301 (29.7%) | 409 (33.7%) | |
| NA | 61 (6.0%) | 52 (4.3%) | |
| Grade | <0.01 | ||
| High | 88 (8.7%) | 271 (22.3%) | |
| Low | 906 (89.5%) | 901 (74.3%) | |
| NA | 18 (1.8%) | 41 (3.4%) | |
| MSI status | 1.00 | ||
| MSI | 88 (8.7%) | 50 (4.1%) | |
| MSS | 614 (60.7%) | 352 (29.0%) | |
| NA | 310 (30.6%) | 811 (66.9%) | |
| DR | <0.01 | ||
| Mature | 507 (50.1%) | 621 (51.2%) | |
| Middle | 354 (35.0%) | 294 (24.2%) | |
| Immature | 151 (14.9%) | 298 (24.6%) |
NOTE: CEA was available in 2,112 patients. MSI status was available in 1,104 patients and grade was available in 2,165 patients. Others were available in all patients.
Abbreviations: CEA, carcinoembryonic antigen; DR, desmoplastic reaction; NA, not available; MSI, microsatellite instability; MSS, microsatellite stability; TNM, tumor-node-metastasis.